{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:15:48Z","timestamp":1791656148644,"version":"4.3.4"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"DOI":"10.1182\/hematology.2022000387","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:13:48Z","timestamp":1670602428000},"page":"586-593","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Perioperative hemostasis for patients with hemophilia"],"prefix":"10.1182","volume":"2022","author":[{"given":"Jacqueline N","family":"Poston","sequence":"first","affiliation":[{"name":"1 Department of Medicine and Department of Pathology, Larner College of Medicine at the University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kruse-Jarres","sequence":"additional","affiliation":[{"name":"2 Washington Center for Bleeding Disorders, Seattle, WA"},{"name":"3 Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"2022120916095862200_hem2022000387C1","doi-asserted-by":"crossref","unstructured":"Srivastava\n              A\n            , SantagostinoE, DougallA, et al; World Federation of Hemophilia Guidelines for the Management of Hemophilia panelists and coauthors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158. doi:10.1111\/hae.14046.","DOI":"10.1111\/hae.14046"},{"key":"2022120916095862200_hem2022000387C2","unstructured":"Hemophilia Foundation\u2019s Medical and Scientific Advisory Council. MASAC document 236\u2014recommendations on standardized testing and surveillance for inhibitors in patients with hemophilia A and B. https:\/\/www.hemophilia.org\/healthcare-professionals\/guidelines-on-care\/masac-documents\/masac-document-236-recommendations-on-standardized-testing-and-surveillance-for-inhibitors-in-patients-with-hemophilia-a-and-b. Accessed 17October2022."},{"issue":"5","key":"2022120916095862200_hem2022000387C3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1160\/TH13-08-0690","article-title":"Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays","volume":"111","author":"Pavlova","year":"2014","journal-title":"Thromb Haemost"},{"key":"2022120916095862200_hem2022000387C4","unstructured":"National Hemophilia Foundation Medical and Scientific Advisory Council. MASAC document 268\u2014recommendation on the use and management of emicizumab-kxwh (Hemlibra\u00ae) for hemophilia A with and without inhibitors. https:\/\/www.hemophilia.org\/healthcare-professionals\/guidelines-on-care\/masac-documents\/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors. Accessed 17October2022."},{"issue":"1","key":"2022120916095862200_hem2022000387C5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/asheducation-2015.1.41","article-title":"Managing older patients with hemophilia","volume":"2015","author":"Angelini","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"2022120916095862200_hem2022000387C6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1055\/s-0032-1328881","article-title":"Drugs that affect platelet function","volume":"38","author":"Scharf","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"December","key":"2022120916095862200_hem2022000387C7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.thromres.2019.06.009","article-title":"Acquired platelet function disorders","volume":"196","author":"Brennan","year":"2020","journal-title":"Thromb Res"},{"issue":"1","key":"2022120916095862200_hem2022000387C8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s13167-018-0158-2","article-title":"Review of herbal medications with the potential to cause bleeding: dental implications, and risk prediction and prevention avenues","volume":"10","author":"Abebe","year":"2019","journal-title":"EPMA J"},{"issue":"11","key":"2022120916095862200_hem2022000387C9","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2022120916095862200_hem2022000387C10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2516.2000.00367.x","article-title":"Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients","volume":"6","author":"Dunn","year":"2000","journal-title":"Haemophilia"},{"issue":"4","key":"2022120916095862200_hem2022000387C11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1046\/j.1365-2141.2000.02067.x","article-title":"Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders","volume":"109","author":"Nolan","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"2022120916095862200_hem2022000387C12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/s12891-022-05535-y","article-title":"Hidden blood loss of total knee arthroplasty in hemophilia arthritis: an analysis of influencing factors","volume":"23","author":"Shen","year":"2022","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"2022120916095862200_hem2022000387C13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jth.15654","article-title":"Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: a prospective multicenter observational study","volume":"20","author":"Kleiboer","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2022120916095862200_hem2022000387C14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ejh.13348","article-title":"The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients","volume":"104","author":"Cai","year":"2020","journal-title":"Eur J Haematol"},{"issue":"1","key":"2022120916095862200_hem2022000387C15","first-page":"42","article-title":"Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery","volume":"116","author":"Buckner","year":"2016","journal-title":"Thromb Haemost"},{"issue":"5","key":"2022120916095862200_hem2022000387C16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2516.2008.01748.x","article-title":"The role of physiotherapy after total knee arthroplasty in patients with haemophilia","volume":"14","author":"Lobet","year":"2008","journal-title":"Haemophilia"},{"issue":"suppl 3","key":"2022120916095862200_hem2022000387C17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2516.2006.01266.x","article-title":"Physiotherapy following elective orthopaedic procedures","volume":"12","author":"De Kleijn","year":"2006","journal-title":"Haemophilia"},{"issue":"2)(suppl 1","key":"2022120916095862200_hem2022000387C18","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1053\/j.seminhematol.2008.03.009","article-title":"Controversies and challenges in elective orthopedic surgery in patients with hemophilia and inhibitors","volume":"45","author":"Jim\u00e9nez-Yuste","year":"2008","journal-title":"Semin Hematol"},{"issue":"10","key":"2022120916095862200_hem2022000387C19","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"3","key":"2022120916095862200_hem2022000387C20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"issue":"21","key":"2022120916095862200_hem2022000387C21","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2022120916095862200_hem2022000387C22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"6","key":"2022120916095862200_hem2022000387C23","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2010-02-261891","article-title":"Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences","volume":"116","author":"Lisman","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2022120916095862200_hem2022000387C24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","article-title":"AGA clinical practice update: coagulation in cirrhosis","volume":"157","author":"O'Leary","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"2022120916095862200_hem2022000387C25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jhep.2021.09.003","article-title":"EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"76","author":"European Association for the Study of the Liver","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"2022120916095862200_hem2022000387C26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jth.15562","article-title":"Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH","volume":"20","author":"Roberts","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2022120916095862200_hem2022000387C27","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1053\/j.gastro.2021.08.015","article-title":"American Gastroenterological Association Institute clinical practice guideline on the management of coagulation disorders in patients with cirrhosis","volume":"161","author":"O'Shea","year":"2021","journal-title":"Gastroenterology"},{"issue":"16","key":"2022120916095862200_hem2022000387C28","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJM196910162811603","article-title":"Acquired circulating anticoagulants in hemophilia A","volume":"281","author":"Strauss","year":"1969","journal-title":"N Engl J Med"},{"issue":"4","key":"2022120916095862200_hem2022000387C29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/hae.14322","article-title":"Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery","volume":"27","author":"Jim\u00e9nez-Yuste","year":"2021","journal-title":"Haemophilia"},{"issue":"9","key":"2022120916095862200_hem2022000387C30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2022120916095862200_hem2022000387C31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/hae.13807","article-title":"Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: final results of a multicentre, single-arm phase III trial","volume":"25","author":"Gruppo","year":"2019","journal-title":"Haemophilia"},{"issue":"4","key":"2022120916095862200_hem2022000387C32","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1111\/hae.14319","article-title":"Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A","volume":"27","author":"Santagostino","year":"2021","journal-title":"Haemophilia"},{"key":"2022120916095862200_hem2022000387C33","article-title":"Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: real-world experience in the Nordic countries. [published online ahead of print 16 May 2022]","author":"Lehtinen","journal-title":"Haemophilia"},{"issue":"2","key":"2022120916095862200_hem2022000387C34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15084","article-title":"Recent advances in developing specific therapies for haemophilia","volume":"181","author":"Ling","year":"2018","journal-title":"Br J Haematol"},{"key":"2022120916095862200_hem2022000387C35","unstructured":"Eloctate. Package insert. https:\/\/www.fda.gov\/media\/88746\/download. Accessed 17October2022."},{"key":"2022120916095862200_hem2022000387C36","unstructured":"Adynovate. Package insert. https:\/\/www.fda.gov\/media\/94470\/download. Accessed 17October2022."},{"key":"2022120916095862200_hem2022000387C37","unstructured":"Esperoct. Package insert. https:\/\/www.fda.gov\/media\/120351\/download. Accessed 17October2022."},{"key":"2022120916095862200_hem2022000387C38","unstructured":"Jivi. Package insert. https:\/\/www.fda.gov\/files\/vaccines,%20blood%20%26%20biologics\/published\/Package-Insert-JIVI.pdf. Accessed 17October2022."},{"key":"2022120916095862200_hem2022000387C39","unstructured":"Alprolix. Package insert. https:\/\/www.fda.gov\/media\/88119\/download. Accessed 17October2022."},{"key":"2022120916095862200_hem2022000387C40","unstructured":"Idelvion. Package insert. https:\/\/www.fda.gov\/media\/96526\/download. Accessed 17October2022."},{"key":"2022120916095862200_hem2022000387C41","unstructured":"Rebinyn. Package insert. https:\/\/www.fda.gov\/files\/vaccines,%20blood%20&%20biologics\/published\/Package-Insert-REBINYN.pdf. Accessed 17October2022."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/586\/2021893\/586poston.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/586\/2021893\/586poston.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:14:15Z","timestamp":1670602455000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/586\/493562\/Perioperative-hemostasis-for-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000387","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}